Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms
First Claim
Patent Images
1. A crystalline form of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′
- -(4-(2-methylpropyloxy)phenylmethyl)carbamide having substantially the same X-ray powder diffraction pattern as depicted in FIG. 1.
0 Assignments
0 Petitions
Accused Products
Abstract
Disclosed herein are methods for synthesizing N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)-phenylmethyl)carbamide. Also disclosed herein is the hemi-tartrate salt of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)-phenylmethyl)carbamide and methods for obtaining the salt. Further disclosed are various crystalline forms of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)-phenylmethyl)carbamide and its hemi-tartrate salt including various polymorphs and solvates.
-
Citations
7 Claims
-
1. A crystalline form of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′
- -(4-(2-methylpropyloxy)phenylmethyl)carbamide having substantially the same X-ray powder diffraction pattern as depicted in
FIG. 1 .
- -(4-(2-methylpropyloxy)phenylmethyl)carbamide having substantially the same X-ray powder diffraction pattern as depicted in
-
2. A crystalline form of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′
- -(4-(2-methylpropyloxy)phenylmethyl)carbamide hemi-tartrate having substantially the same X-ray powder diffraction pattern as depicted in
FIG. 2 .
- -(4-(2-methylpropyloxy)phenylmethyl)carbamide hemi-tartrate having substantially the same X-ray powder diffraction pattern as depicted in
-
3. A crystalline form of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′
- -(4-(2-methylpropyloxy)phenylmethyl)carbamide hemi-tartrate having substantially the same X-ray powder diffraction pattern as depicted in
FIG. 3 .
- -(4-(2-methylpropyloxy)phenylmethyl)carbamide hemi-tartrate having substantially the same X-ray powder diffraction pattern as depicted in
-
4. A crystalline form of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′
- -(4-(2-methylpropyloxy)phenylmethyl)carbamide hemi-tartrate having substantially the same X-ray powder diffraction pattern as depicted in
FIG. 4 .
- -(4-(2-methylpropyloxy)phenylmethyl)carbamide hemi-tartrate having substantially the same X-ray powder diffraction pattern as depicted in
-
5. A crystalline form of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′
- -(4-(2-methylpropyloxy)phenylmethyl)carbamide hemi-tartrate having substantially the same X-ray powder diffraction pattern as depicted in
FIG. 5 .
- -(4-(2-methylpropyloxy)phenylmethyl)carbamide hemi-tartrate having substantially the same X-ray powder diffraction pattern as depicted in
-
6. A crystalline form of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′
- -(4-(2-methylpropyloxy)phenylmethyl)carbamide hemi-tartrate having substantially the same X-ray powder diffraction pattern as depicted in
FIG. 6 .
- -(4-(2-methylpropyloxy)phenylmethyl)carbamide hemi-tartrate having substantially the same X-ray powder diffraction pattern as depicted in
-
7. A crystalline form of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′
- -(4-(2-methylpropyloxy)phenylmethyl)carbamide hemi-tartrate having substantially the same X-ray powder diffraction pattern as depicted in
FIG. 7 .
- -(4-(2-methylpropyloxy)phenylmethyl)carbamide hemi-tartrate having substantially the same X-ray powder diffraction pattern as depicted in
Specification